共 35 条
- [31] Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial (vol 6, pg 681, 2018) LANCET RESPIRATORY MEDICINE, 2018, 6 (09): : E50 - E50
- [33] Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to firstline (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC) ANNALS OF ONCOLOGY, 2022, 33 (07) : S1050 - S1051
- [34] Retrospective clinical analysis of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC) JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
- [35] EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC) EJC SUPPLEMENTS, 2009, 7 (04): : 10 - 10